
Sudden vision loss in one eye calls for a same day eye check like this one.
MC2 Jonathan Jiang, U.S. Navy
Illustrative. Not a patient with NAION and not connected to the FDA analysis.
Every GLP-1 Drug Now Carries an Eye Warning. Here Is How Small the Risk Really Is
For two years the question of whether GLP-1 drugs can damage the optic nerve has bounced between alarming headlines and reassuring rebuttals. On November 9, FDA stopped waiting for a perfect answer and put a warning on every label in the class.
- On November 9, 2026, FDA required every GLP-1 receptor agonist, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about NAION, a rare cause of sudden, painless vision loss in one eye.
- In FDA's pooled analysis of 126 randomized trials, NAION was rare in both groups: 10 cases on GLP-1 drugs and 5 on placebo, about 6.4 versus 3.8 per 100,000 person years.
- FDA calls the risk potential, not proven. The practical message is symptom awareness: sudden vision loss in one eye needs same day care, and nobody should stop a prescription on their own.
What FDA actually did
FDA issued a Drug Safety Communication requiring all GLP-1 receptor agonists to add a potential increased risk of nonarteritic anterior ischemic optic neuropathy, NAION for short, to the Warnings and Precautions section of their labels. The list covers the familiar brands, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda and Trulicity.
NAION happens when blood flow to the front of the optic nerve drops. It usually shows up as sudden, painless loss of vision in one eye, and the damage can be permanent. It is uncommon in anyone: FDA puts the background rate at 2.3 to 10.2 cases per 100,000 adults over 50 each year.
The numbers behind the warning
The concern started with a 2024 observational study in JAMA Ophthalmology that linked semaglutide to NAION at a single eye center. FDA then ran its own pooled analysis of 126 randomized trials covering 134,253 patients and 288,879 person years of follow up.
Across all of that, FDA counted 15 probable NAION events: 10 in people taking a GLP-1 drug, 5 on placebo and none on other diabetes drugs. That works out to about 6.4 versus 3.8 cases per 100,000 person years. Put plainly, the difference is roughly 2.6 extra cases for every 100,000 people treated for a year, a calculation from FDA's two rates rather than a figure FDA states.
On a GLP-1 drug
NAION cases per 100,000 person years in FDA's pooled trials.
On placebo
Same measure, same trials.
Events in total
Ten on GLP-1 drugs, five on placebo, across 126 trials.
126 randomized trials, 134,253 patients, 288,879 person years. FDA gives no confidence interval for this comparison.
FDA also checked its Sentinel database of adults with type 2 diabetes from 2019 to 2024. Compared with SGLT-2 inhibitors, GLP-1 users had a hazard ratio of 1.19, with a confidence interval of 0.91 to 1.54 that includes no difference at all. Compared with DPP-4 inhibitors, the hazard ratio was 1.43, with an interval of 1.02 to 2.01.
Why the evidence is still unsettled
Fifteen events is a very small number to build a ratio on, and FDA's page gives no confidence interval for the trial comparison. One of the two Sentinel comparisons did not reach significance. Animal studies have not found a mechanism.
A label warning is how regulators act on a signal that is credible but not settled.
There is also a confounding problem built into the population. The conditions that raise NAION risk, such as diabetes, high blood pressure and sleep apnea, are common in exactly the people who take these drugs. FDA says that made individual adverse event reports hard to interpret, and that is why it leaned on trials and comparisons between drug users rather than case reports.
A label warning is how regulators act on a signal that is credible but not settled. It is not a finding that the drugs cause blindness.
Honest caveat
FDA's own wording is a potential increased risk. The trial pooling rests on 15 events, the comparison against SGLT-2 inhibitors was not statistically significant, and no biological mechanism has been identified. The exact new label text was not shown on FDA's page. The extra cases per 100,000 figure is arithmetic from FDA's two published rates. This is not medical advice.
What this means for you
If you take a GLP-1 drug, the useful thing to know is the symptom, not the statistic. Sudden loss of vision in one eye, a new blind spot or washed out color in one eye is a reason to get seen the same day, whatever medicine you take.
Do not stop or change a prescription on your own because of this warning. If you already have risk factors for NAION, such as a prior episode, sleep apnea or poorly controlled blood pressure, it is a reasonable question to raise with whoever prescribes the drug. And a supplement marketed as supporting GLP-1 is not a GLP-1 drug, so this warning neither applies to it nor says anything about its safety.
Primary sources
Common questions
Does this mean GLP-1 drugs cause blindness?
No. FDA describes a potential increased risk of NAION, a rare condition. In its pooled trials NAION occurred in about 6.4 per 100,000 person years on GLP-1 drugs versus 3.8 on placebo, based on 15 events in total, and no mechanism has been found.
Which drugs does the warning cover?
Every GLP-1 receptor agonist, including semaglutide products such as Ozempic, Wegovy and Rybelsus, tirzepatide products such as Mounjaro and Zepbound, and older drugs such as Victoza, Saxenda and Trulicity.
What symptoms should I watch for?
Sudden, usually painless loss of vision in one eye, or a new blind spot or dimmed color in one eye. That needs same day medical care. Talk to your prescriber before changing any medicine.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.